Cargando…

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy

PURPOSE: The aim of this meta-analysis was to evaluate the efficacy and safety of imidafenacin for overactive bladder (OAB) induced by benign prostatic hyperplasia (BPH) in men receiving alpha-blocker monotherapy. METHODS: We performed a systematic research of the PubMed, Embase, and Cochrane Librar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Tong, Wang, Ning, Liang, Liye, Zhou, Zhongbao, Zhang, Yong, Cui, Yuanshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Continence Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788324/ https://www.ncbi.nlm.nih.gov/pubmed/33401358 http://dx.doi.org/10.5213/inj.2040146.073

Ejemplares similares

A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
por: Yamanishi, Tomonori, et al.
Publicado: (2018)

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
por: Kwon, Se Yun, et al.
Publicado: (2020)

Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature
por: Masumori, Naoya
Publicado: (2013)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
por: Wang, Hui, et al.
Publicado: (2017)

The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis
por: Su, Shunye, et al.
Publicado: (2020)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis
por: Cai, Tong, et al.
Publicado: (2020)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
por: Lee, Cheng-Ling, et al.
Publicado: (2023)

Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)
por: Hagovska, Magdalena, et al.
Publicado: (2021)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials
por: Zhou, Zhongbao, et al.
Publicado: (2020)

Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study
por: Nishimura, Akihiko, et al.
Publicado: (2021)

Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)
por: Zaitsu, Masayoshi, et al.
Publicado: (2011)

Increased detrusor collagen is associated with detrusor overactivity and decreased bladder compliance in men with benign prostatic obstruction
por: Bellucci, Carlos H.S., et al.
Publicado: (2017)

Reply to Commentary on “Role of Transcutaneous Electrical Nerve Stimulation in Treating Children With Overactive Bladder From Pooled Analysis of 8 Randomized Controlled Trials”
por: Zhou, Zhongbao, et al.
Publicado: (2020)

Effect of imidafenacin on the urodynamic parameters of patients with indwelling bladder catheters due to spinal cord injury
por: Sugiyama, H, et al.
Publicado: (2017)

Efficacy of Alpha Blocker Treatment According to the Degree of Intravesical Prostatic Protrusion Detected by Transrectal Ultrasonography in Patients with Benign Prostatic Hyperplasia
por: Park, Hee Young, et al.
Publicado: (2012)

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States
por: DerSarkissian, Maral, et al.
Publicado: (2016)

Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study
por: Takahashi, Satoru, et al.
Publicado: (2020)

The Efficacy and Safety of Holmium Laser Enucleation of Prostate Compared With Bipolar Technologies in Treating Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials
por: Che, Xuanyan, et al.
Publicado: (2022)

Benign prostatic hyperplasia and subsequent risk of bladder cancer
por: Kang, D, et al.
Publicado: (2007)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men
por: Han, Zihua, et al.
Publicado: (2017)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
por: Takahashi, Hiroshi, et al.
Publicado: (2019)

International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients
por: Nishimura, Akihiko, et al.
Publicado: (2022)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction
por: Patel, Nishant D., et al.
Publicado: (2014)

Risk factors for bladder calculi in patients with benign prostatic hyperplasia
por: Huang, Wei, et al.
Publicado: (2017)

Importance of prostate volume and urinary flow rate in prediction of bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia
por: Trumbeckas, Darius, et al.
Publicado: (2011)

Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan
por: Masumori, Naoya, et al.
Publicado: (2016)

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
por: Choi, Jae Hwi, et al.
Publicado: (2014)

Benign Prostatic Hyperplasia
Publicado: (2015)

Ultrasonographic Intravesical Prostatic Protrusion in Men with Benign Prostatic Hyperplasia in Southwest Nigeria
por: Okedere, Tolulope Adebayo, et al.
Publicado: (2023)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia
por: Kim, Su Kang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b6gsolumn0ip3l5pmmslpq8auj